What are the mechanisms of action of sacubitril/valsartan (angiotensin‑neprilysin inhibitor), beta‑blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, and how do they work together as the four pillars of heart failure therapy?

Four Pillars of Heart Failure Therapy: Mechanisms and Synergistic Action

The four pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) consist of sacubitril/valsartan (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors—each targeting distinct pathophysiological mechanisms that work synergistically to reduce cardiovascular death and heart failure hospitalization. 1, 2, 3

Individual Mechanisms of Action

1. Sacubitril/Valsartan (Angiotensin Receptor-Neprilysin Inhibitor)

Dual mechanism combining neprilysin inhibition with angiotensin II receptor blockade:

• Sacubitril component: Metabolized to LBQ657, which inhibits neprilysin (neutral endopeptidase), preventing degradation of natriuretic peptides (ANP, BNP), bradykinin, adrenomedullin, and substance P 4
• Valsartan component: Selectively blocks the angiotensin II type-1 (AT1) receptor, preventing angiotensin II-mediated vasoconstriction and aldosterone release 4

Net physiological effects: Increased natriuretic peptide levels promote vasodilation, natriuresis, diuresis, and inhibition of cardiac remodeling, while simultaneously blocking the harmful effects of angiotensin II 4. In PARADIGM-HF, this combination reduced cardiovascular death or heart failure hospitalization by 20% compared to enalapril (HR 0.80; 95% CI 0.73-0.87) 1.

2. Beta-Blockers

Mechanism: Competitively block beta-adrenergic receptors (primarily β1 in the heart), reducing the harmful effects of chronic sympathetic nervous system activation 1.

Physiological effects:

• Decrease heart rate and myocardial oxygen demand
• Reduce cardiac remodeling and myocyte apoptosis
• Improve left ventricular ejection fraction over time
• Decrease arrhythmogenic potential

Beta-blockers are Grade A recommended for initial therapy in HFrEF with ejection fraction <40% 1.

3. Mineralocorticoid Receptor Antagonists (MRAs)

Mechanism: Competitively inhibit aldosterone binding to mineralocorticoid receptors in the heart, kidneys, and vasculature 1.

Physiological effects:

• Reduce sodium and water retention
• Decrease myocardial and vascular fibrosis
• Reduce potassium excretion (causing hyperkalemia risk)
• Attenuate cardiac remodeling independent of blood pressure effects

MRAs are recommended for patients with recent cardiovascular hospitalization, elevated natriuretic peptides, or NYHA class II-IV symptoms, with careful monitoring for hyperkalemia 1.

4. SGLT2 Inhibitors (Dapagliflozin, Empagliflozin)

Mechanism: Inhibit sodium-glucose co-transporter 2 in the proximal renal tubule, blocking glucose reabsorption 5.

Physiological effects (benefits extend beyond glycemic control):

• Osmotic diuresis with natriuresis (reducing preload)
• Modest blood pressure reduction (reducing afterload)
• Potential shift in myocardial energy substrate toward more efficient glucose oxidation
• Possible modulation of renal sympathetic tone
• Reduction in myocardial mass
• Increased hematocrit

Critical advantage: SGLT2 inhibitors do not affect blood pressure, heart rate, or potassium levels significantly, require no dose titration, and work independently of diabetes status 6. In DAPA-HF, dapagliflozin reduced the primary endpoint by 26% (HR 0.74; 95% CI 0.65-0.85) in both diabetic and non-diabetic patients 5.

How the Four Pillars Work Together

Complementary Pathophysiological Targeting

Each pillar addresses a distinct mechanism in heart failure progression:

1. ARNI: Enhances natriuretic peptide effects while blocking renin-angiotensin-aldosterone system (RAAS)
2. Beta-blockers: Counteract sympathetic nervous system overactivation
3. MRAs: Block aldosterone-mediated fibrosis and sodium retention
4. SGLT2 inhibitors: Provide metabolic, hemodynamic, and neurohormonal benefits independent of the other three pathways

Synergistic Benefits Without Interference

The efficacy of each drug class is independent of the others 6, 7. In DAPA-HF, >90% of patients were on ACE inhibitors/ARBs and beta-blockers, >70% on MRAs, and ~11% on ARNIs at baseline—yet dapagliflozin still provided significant additional benefit 5. An indirect comparison of EMPHASIS-HF (MRA), PARADIGM-HF (ARNI), and DAPA-HF (SGLT2i) suggests comprehensive therapy with all four pillars may further reduce death and worsening heart failure compared to standard treatment 6.

Facilitating Tolerability

SGLT2 inhibitors may enhance tolerability of other foundational drugs:

• In EMPEROR-Reduced, empagliflozin reduced the need for diuretic intensification even in congested patients 6
• Empagliflozin facilitated MRA use by reducing severe hyperkalemia risk and MRA discontinuation 6
• SGLT2 inhibitors' lack of effect on blood pressure and heart rate allows easier titration of ARNIs and beta-blockers 6

Optimal Sequencing Strategy

Modern evidence supports rapid initiation of all four pillars within 2-4 weeks rather than sequential titration over months 7:

1. Week 0-1: Simultaneously start beta-blocker + SGLT2 inhibitor (both well-tolerated, SGLT2i requires no titration)
2. Week 1-2: Initiate sacubitril/valsartan (after beta-blocker stabilizes heart rate)
3. Week 2-4: Add MRA (after ARNI stabilizes blood pressure and renal function)

Rationale: Low starting doses of all four classes provide substantial benefit, and achieving low doses of all four takes precedence over up-titrating individual agents to target doses 2, 7. This approach is safe and results in improved clinical outcomes 8.

Common Pitfalls and Monitoring

Critical monitoring parameters when combining therapies:

• Hypotension: ARNI + beta-blocker combination; may require diuretic dose reduction to permit ARNI titration 2
• Hyperkalemia: ARNI + MRA combination requires potassium monitoring at 2-3 days, monthly for 3 months, then every 3 months 1, 2
• Renal function: Monitor eGFR with ARNI + MRA; SGLT2 inhibitors cause transient eGFR drop but provide long-term kidney protection 6
• Bradycardia: Beta-blocker effects; if heart rate remains ≥70 bpm on maximally tolerated beta-blocker, consider adding ivabradine 2

SGLT2 inhibitor-specific requirements:

• Ensure eGFR >30 mL/min/1.73 m² for dapagliflozin, >60 mL/min/1.73 m² for empagliflozin before initiation 2
• Monitor for genitourinary infections and diabetic ketoacidosis (rare) 9

The four pillars represent a paradigm shift from sequential, slow titration to rapid, comprehensive implementation of disease-modifying therapy, with each agent providing independent and additive mortality and morbidity benefits 3, 8.